EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses

Lei Sun iD, Mengting Huang iD, Simin Feng iD, Wei Zhang, Yun Quan, Ruyi Chen, Yupeng Yang, Haidong Xu, Wansheng Li, Qianyu Pan, Xinwen Chen iD, Danyang Zhang und 7 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.01209-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Lei Sun und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, …. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Immunity, Humoral, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou National Laboratory, National Natural Science Foundation of China, Guangdong Provincial Department of Science and Technology, The Pearl River Talent Recruitment Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease (LRTD) in infants, the elderly, and immunocompromised individuals. In this study, we leveraged the innovative EABR (ESCRT- and ALIX-binding region) vaccine technology to develop a pre-fusion (Pre-F)-based RSV mRNA vaccine (Pre-F-EABR) that encodes self-assembling enveloped virus-like particles (eVLPs). In vitro expression of Pre-F-EABR mRNA manifested pronounced Pre-F protein expression, particularly on cell membranes and in cell culture supernatant, compared to classical Pre-F and Pre-F-Ferritin nanoparticle (Pre-F-Fe) mRNAs, suggesting efficient eVLP self-assembly. Immunization of mice with lipid nanoparticle-encapsulated, nucleoside-modified mRNAs (mRNA-LNPs) demonstrated that the Pre-F-EABR vaccine elicited enhanced neutralizing activities and more robust cellular immunity when compared to Pre-F or Pre-F-Fe mRNA vaccines. Notably, the Pre-F-EABR mRNA vaccine induced a significantly higher level of protective pre-fusion-specific antibodies in contrast to post-fusion-targeting antibodies, dramatically reducing pulmonary viral load following RSV challenge in vaccinated mice. Furthermore, the Pre-F-EABR mRNA vaccine demonstrated significantly improved efficacy against the contemporary clinical ON1 and BA9 isolates. Overall, these findings demonstrate that the Pre-F-EABR mRNA vaccine induces more robust immune responses, highlighting its potential in preventing RSV infection in vulnerable populations. IMPORTANCE Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants, the elderly, and immunocompromised individuals. It is well-established that enhancing the neutralizing antibody levels and Th1-biased cellular immune responses can potentially improve the efficacy and safety of RSV vaccines. In this study, we developed an RSV pre-fusion protein-based mRNA vaccine that encodes self-assembling enveloped virus-like particles. Mice immunized with this vaccine showed significantly enhanced pre-fusion protein-targeted humoral responses and improved protection against RSV infection compared to the conventional RSV mRNA vaccine. Additionally, this vaccine demonstrated a considerably stronger neutralizing ability against contemporary clinical RSV isolates and induced more robust Th1-biased cellular immune responses, suggesting its potential as a promising RSV vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesImmunity, HumoralRespiratory Syncytial Virus, HumanViral Fusion ProteinsVaccines, Virus-Like ParticleAnimalsMiceAntibodies, ViralHumansFemaleAntibodies, NeutralizingMice, Inbred BALB CRNA, MessengerImmunity, CellularNanoparticles

Stichwörter der Autor:innen

EABReVLPsimmune responsesmRNA vaccinerespiratory syncytial virus

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralViral Fusion ProteinsAntibodies, NeutralizingVaccines, Virus-Like ParticleRNA, Messenger

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.
  • Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
  • State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
  • Zhangjiang mRNA Innovation and Translation Center, Fudan University, Shanghai, China.

ORCID-Profile: Lei Sun, Mengting Huang, Simin Feng, Xinwen Chen, Jincun Zhao, Zhongfang Wang, Martin Ludlow, Qiong Zhang

Förderung

  • Guangzhou National Laboratory
  • National Natural Science Foundation of China
  • Guangdong Provincial Department of Science and Technology, The Pearl River Talent Recruitment Program

Zitieren

APA

Sun, L., Huang, M., Feng, S., Zhang, W., Quan, Y., Chen, R., Yang, Y., Xu, H., Li, W., Pan, Q., Chen, X., Zhang, D., Yuan, B., Zhao, J., Wang, Z., Lin, J., Peng, W., Ludlow, M., & Zhang, Q. (2025). Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses. Journal of Virology. https://doi.org/10.1128/jvi.01209-25

Vancouver

Sun L, Huang M, Feng S, Zhang W, Quan Y, Chen R, et al. Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses. Journal of Virology. 2025. doi:10.1128/jvi.01209-25

BibTeX
@article{Sun2025,
  author = {Sun, Lei and Huang, Mengting and Feng, Simin and Zhang, Wei and Quan, Yun and Chen, Ruyi and Yang, Yupeng and Xu, Haidong and Li, Wansheng and Pan, Qianyu and Chen, Xinwen and Zhang, Danyang and Yuan, Bin and Zhao, Jincun and Wang, Zhongfang and Lin, Jinzhong and Peng, Wei and Ludlow, Martin and Zhang, Qiong},
  title = {Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01209-25}
}
Kostenlos starten →